retatrutide triple agonist gip glp-1 glucagon phase 3 2025 π¨ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. π Mean body weight change at 80 weeks: β¬οΈ Retatrutide: The "Triple G" Peptide
Pay in 4 interest-free payments of $6.70 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 11 - Aug 16



























